Influenza vaccine GSK1562902A Formulation 2 — Competitive Intelligence Brief

Influenza vaccine GSK1562902A Formulation 2 (Influenza vaccine GSK1562902A Formulation 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology.

phase 3 Inactivated influenza vaccine Immunology Biologic

Target snapshot

Influenza vaccine GSK1562902A Formulation 2 (Influenza vaccine GSK1562902A Formulation 2) — GlaxoSmithKline. This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Influenza vaccine GSK1562902A Formulation 2 TARGET	Influenza vaccine GSK1562902A Formulation 2	GlaxoSmithKline	phase 3	Inactivated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
High Dose Trivalent Influenza Vaccine	High Dose Trivalent Influenza Vaccine	Brigham and Women's Hospital	marketed	Inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class